Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease

Simon Dujardin(Centre Hospitalier Universitaire de Lille), Bradley T. Hyman(Harvard University), Matthew P. Frosch(Harvard University), Tarun Kamath(Harvard University), Lori B. Chibnik(Harvard University), Arthur Viodé(Boston Children's Hospital), Mark B. De Los Santos(Massachusetts General Hospital), Naomi Klickstein(Massachusetts General Hospital), Fiona Elwood(Novartis (Switzerland)), Alberto Serrano‐Pozo(Harvard University), Rudolph E. Tanzi(Harvard University), Ben D. Moore(Western Sydney University), Matthew Kennedy(Merck & Co., Inc., Rahway, NJ, USA (United States)), Bianca T. Corjuc(Harvard University), Diana L. Corjuc(Massachusetts General Hospital), Renée Moore(Merck & Co., Inc., Rahway, NJ, USA (United States)), Judith A. Steen(Boston Children's Hospital), Kevin Atchison(Merck & Co., Inc., Rahway, NJ, USA (United States)), Aurélien Lathuilière(University of Geneva), Derek H. Oakley(Massachusetts General Hospital), Caitlin Commins(Harvard University), Pieter Beerepoot(Boston Children's Hospital), Dinorah Jean-Gilles(Merck & Co., Inc., Rahway, NJ, USA (United States)), Analiese R. Fernandes(Massachusetts General Hospital), Patrick M. Dooley(Massachusetts General Hospital), Ryan Clark(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kristina Mullin(Harvard University)
Nature Medicine
June 22, 2020
Cited by 445


Related Papers